Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 5/20 | 0.44 |
| ▸ | GIPR | P48546 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13109739 | 0.93 | PPARD (0.43) | GCGRGIPRPOLBTSHRALDH1A1 | |
| SCHEMBL3452039 | 0.93 | MEN1 (0.43) | GCGRGIPRPOLBTSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL3452688 | 0.92 | MEN1 (0.42) | GCGRGIPRPOLBTSHRALDH1A1 | |
| SCHEMBL3453310 | 0.91 | MEN1 (0.46) | GCGRGIPRPOLBTSHRALDH1A1 | |
| SCHEMBL3452451 | 0.91 | ALDH1A1 (0.42) | GCGRGIPRPOLBTSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL3451239 | 0.91 | MEN1 (0.45) | GCGRGIPRPOLBTSHRALDH1A1 | |
| SCHEMBL1833263 | 0.90 | MEN1 (0.42) | GCGRGIPRPOLBTSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL3453214 | 0.90 | ALDH1A1 (0.41) | POLBTSHRALDH1A1KDM4EHPGD | |
| SCHEMBL13109743 | 0.90 | KDM4E (0.43) | GCGRGIPRPOLBTSHRALDH1A1 | |
| SCHEMBL13109421 | 0.90 | ALDH1A1 (0.52) | POLBTSHRALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | claimed |
| CN-1946703-A | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators | TRANSTECH PHARMA INC (US) | 2007-04-11 | — | — | CN | claimed |
| EP-1753735-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | Transtech Pharma, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-11-24 | — | — | US | claimed |
| WO-2005103022-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | TRANSTECH PHARMA, INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-8563742-B2 | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563742-B2 | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100056587-A1 | Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use | VTVX HOLDINGS I LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100056587-A1 | Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use | VTVX HOLDINGS I LLC | 2010-03-04 | — | — | US | disclosed |
| WO-2010025142-A1 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| CN-1946703-A | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators | TRANSTECH PHARMA INC (US) | 2007-04-11 | — | — | CN | disclosed |
| EP-1753735-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | Transtech Pharma, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-11-24 | — | — | US | disclosed |
| WO-2005103022-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | TRANSTECH PHARMA, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056587-A1 | Substituted Aminothiazole Derivatives, Pharmaceutical Compositions, And Methods Of Use | MC4R, MC3R, MC5R | GCGR 52/4885GIPR 6/4885POLB 4456/4885 |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | MC5R, MC3R, MC4R | GCGR 16/4885GIPR 6/4885POLB 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.